No use crying over spilt milk

Fonterra has confirmed a record loss of $605m for the FY19 season, no dividend payment and a milk price of $6.35/kg milksolid (MS).

The company has outlined its strategy to concentrate on its core function of manufacturing New Zealand milk into ingredients and food service products. It also has a focus on being more financially and environmentally sustainable.

The previous guidance for FY20 of a milk price in the range of $6.25 - $7.25/kg MS remains unchanged. Earnings for FY20 are forecast to be 15-25c per share with a dividend guidance range reduced to 40-60% of earnings (previously 65-75%) indicating a dividend in the range of 6-15 cents.

Financial results

The net loss of $605m for the 2019 financial year was in line with the guidance previously issued of a $590-675m loss.

Figure 1. Fonterra profit (loss)

Revisions to carrying values of assets (including those divested) and other one-off accounting adjustments were expected to reduce earnings by approximately $820–$860m. The actual adjustment was $826m, at the smaller end of expectations.

Normalised operating expenditure decreased by 7% to $2,311m in the latest financial year. This compared to $2,496m in FY18.

As previously noted there will be no dividend paid for FY19.

Fonterra will be adopting a more conservative dividend payment ratio, with only half (40-60%) of earnings paid out as a dividend and the remainder retained. The previous policy was to pay 65-75% of earnings as a dividend.
Ingredients
The Ingredients section of the business is by far the largest portion of the company. This includes the ingredients business in New Zealand, global sales and marketing of New Zealand ingredients produced in New Zealand, milk supply and manufacturing in Australia, and ingredients in South America.

Normalised EBIT for this division was $811m. This compares to $879m in FY18. A year ago Fonterra forecast this division to achieve an EBIT of $850-950m, so it has fallen short of this target. Revenue increased but so too did the cost of goods sold.

Consumer and Foodservice
The Consumer and Foodservice division achieved a normalised EBIT this season of $450m. This compares unfavourably to an expectation of $540-$590m. Last year the Greater China area accounted for $165m (31%) of the $525m of normalised EBIT achieved by this division. Virtually all geographical segments of the consumer and foodservice division performed more poorly than the previous season. The Oceania section increased its normalised EBIT but this was more than offset by a $204m earnings adjustment.

There was a sharp drop in returns from the Latin America segment as revenue fell while expenses held at previous levels. In addition, a $143m impairment on the Brazil business and costs of $112m associated with the disposal of the Venezuelan operation severely negatively impacted profits.

China Farms
China Farms delivered another operating loss. The loss this year was $14m compared to FY18 where the normalised EBIT was -$9m. However, when looked at on an end-to-end basis this division had a loss of $30m, as a further $20m loss was absorbed by the ingredients business. This is the first time Fonterra has acknowledged the full losses of this division.

Milk available for sale decreased due to issues with floods in Yutian and animal health problems.

Fonterra made it clear today they want to ‘unlock the value’ in China Farms. They do see potential in the fresh milk market in China and expect prices will rise, but said the timing of this is uncertain. This division has consistently been unprofitable so exiting these farming assets is a logical choice for Fonterra. Whether they will be able to do this at current book values remains debatable.

Debt
At the end of the previous financial year the economic net interest-bearing debt (net debt) was $6.2bn. At that time, Fonterra had a debt/earnings ratio of 4.5x and a gearing ratio of 48.4%, and forecast reducing the gearing ratio to 40-45%. However, during the first half of FY19 debt gearing increased to 52.5%.

Fonterra had targeted reducing debt by $800m by the end of FY19, but had previously conceded that it would fall short of this target. Net debt at the end of FY19 now stands at $5.7bn. Debt gearing is at 48.2% and the debt/earnings ratio is at 4.3x.

However, the figure doesn’t take into account the sale of DFE Pharma announced yesterday, as this wasn’t completed before the end of the financial year. Fonterra advised that the sale of DFE Pharma for $633m (inclusive of a $96m vendor loan), means it has now reduced its total debt by $1 billion.

By the end of FY20 Fonterra are forecasting debt of $4.4-4.6m due to the funds from the DFE Pharma sale and improvement in operating efficiency, including higher earnings, lower capex and further divestments, totalling $500-700m.
Asset sales

Fonterra has actively pursued asset sales this year, with the majority of the sales occurring in the second half of FY19. The process of asset sales revealed that a significant number of assets were overvalued on the books. Asset write downs announced earlier this year include:

Table 1. Fonterra asset write downs in FY19 (previously announced).

<table>
<thead>
<tr>
<th>Asset</th>
<th>Country</th>
<th>Write down</th>
</tr>
</thead>
<tbody>
<tr>
<td>Corporacion Inlaca</td>
<td>Venezuela</td>
<td>$135 million</td>
</tr>
<tr>
<td>Dairy Partners Americas</td>
<td>Brazil</td>
<td>$200 million</td>
</tr>
<tr>
<td>China Farms</td>
<td>China</td>
<td>$200 million</td>
</tr>
<tr>
<td>NZ consumer business</td>
<td>NZ</td>
<td>$200 million (net after $100 million gain from TipTop sale)</td>
</tr>
<tr>
<td>Australian ingredient business</td>
<td>Australia</td>
<td>$70 million</td>
</tr>
</tbody>
</table>

No further write downs were announced with the release of the full year financial accounts. The total value of write downs were confirmed to be $826m. This included DPA Brazil, China Farms, Venezuela, Fonterra NZ, Australia Ingredients, and Beingmate.
Table 2. Fonterra asset sales previously announced:

<table>
<thead>
<tr>
<th>Asset</th>
<th>Country</th>
<th>Ownership</th>
<th>Return (NZ$)</th>
<th>Gain/loss on book value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tip Top</td>
<td>NZ</td>
<td>100%</td>
<td>$380m sold to Froneri</td>
<td>+$100m</td>
</tr>
<tr>
<td>Corporacion Inlaca</td>
<td>Venezuela</td>
<td>60%</td>
<td>$16m sold to Mirona</td>
<td>-$126m</td>
</tr>
<tr>
<td>Goodminton AG (foodspring)</td>
<td>Germany</td>
<td>Mars brought large share of foodspring</td>
<td>+$64m</td>
<td></td>
</tr>
<tr>
<td>Fast Forward (JV with First Milk)</td>
<td>UK</td>
<td>51%</td>
<td>Sold to Hoogwegt</td>
<td></td>
</tr>
<tr>
<td>DFE Pharma (JV with Friesland Campina)</td>
<td>Netherlands</td>
<td>50%</td>
<td>$633m sold to CVC Strategic Opportunities II</td>
<td></td>
</tr>
</tbody>
</table>

Table 3. Other assets under review or on the market

<table>
<thead>
<tr>
<th>Asset</th>
<th>Country</th>
<th>Ownership</th>
<th>Value NZ$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beingmate</td>
<td>China</td>
<td>18.8%</td>
<td>Market value estimated to be $223m, Book value $204m.</td>
</tr>
<tr>
<td>China farms Yutian and Ying hubs</td>
<td>China</td>
<td>100%</td>
<td>Book value $548m (livestock valued at $280m).</td>
</tr>
<tr>
<td>Dairy Partners Americas</td>
<td>Brazil</td>
<td>51%</td>
<td>Strategic review underway</td>
</tr>
</tbody>
</table>

In March, Fonterra announced its intention to sell its 50% stake in **DFE Pharma**, a joint venture established in 2006 between Fonterra and Friesland Campina. It produces pharmaceutical excipients which are used as carriers in medicines including tablets and powders. Previous estimates put the market value of DFE Pharma at about $200m. The sale of DFE Pharma to a fund called Strategic Opportunities II was confirmed yesterday. The selling price of $633m includes a $96m interest bearing loan from Fonterra for a 15 year term. The terms of the sale also include continuing to source lactose from Fonterra’s Lactose plant based in Kapuni, Taranaki.

Fonterra continues to hold an 18.8% share in **Beingmate**, which equates to 192.4 million shares. Beingmate shares are currently priced at ¥5.24, about NZD1.16 at the current exchange rate, placing the total value of the investment at $223m. This is above the current book value of Beingmate of $204m. Please note in an earlier Dairy Update we incorrectly advised that Beingmate had a book value of $405m.

**Figure 4. Beingmate share price**

Source: Reuters

Fonterra previously confirmed its intention to exit its investment in Beingmate, as it no longer views it as a strategic investment. Shenzhen Stock Exchange rules limit sales in a share-holding to 1% every 90 days or 2% via a block trade. Trades of more than 5% can only be made in an off-market transaction.
A strategic review of Fonterra’s Dairy Partners America (DPA) business in Brazil commenced earlier this year. This is a joint venture between Nestle and Fonterra, in which Fonterra has the majority shareholding. No further update was given for this business.

Aside from the assets mentioned above we previously advised concerns about the book value of a number of asset (see Table 4)

<table>
<thead>
<tr>
<th>Asset</th>
<th>Country</th>
<th>Potential write down</th>
</tr>
</thead>
<tbody>
<tr>
<td>China Farms</td>
<td>China</td>
<td>$100 - 200 million</td>
</tr>
<tr>
<td>Australian ingredient business</td>
<td>Australia</td>
<td>Up to $100 million</td>
</tr>
<tr>
<td>Soprole / Prolesur</td>
<td>Chile</td>
<td>Up to $200 million</td>
</tr>
</tbody>
</table>

At the end of the 2018 financial year the China Farms business had a book value of $748m, which was subsequently written down to $548m earlier this year. The potential for further write downs was based on the underlying livestock having an asset value of only $280m and the ongoing losses the business continues to incur. Today Fonterra made it clear this division is on the market as it wants to realise the value it currently has tied up in it.

Fonterra’s Australian ingredients business has struggled in recent years, due to the challenges farmers face of rising costs of production resulting in a reduction in milk supply. Fonterra has struggled to retain its share of this reducing pool of milk. In the 2018-19 season, Fonterra’s Australian milk intakes fell by 20.3%, while Australia’s total milk production fell 5.7%. While there are some geographical disparities that have resulted in milk volumes falling more in the regions Fonterra is exposed to, it is also losing milk to its competitors. Fonterra has made no further reference to this division in its announcement today.

Concerns have previously been raised about Fonterra’s Soprole and Prolesure businesses in Chile. Milk intake has fallen in the business in recent years. This business has remained profitable but questions have previously been raised about whether this business is over-valued on the books. No reference was made to the Chilean business in today’s announcement.

Strategy
Fonterra today outlined its new strategy. This essentially focuses on deriving more value from New Zealand milk and continuing to divest non-core (offshore) assets. Fonterra plans to focus on ingredient categories: Paediatrics, Medical and Ageing, Sports and Active, and Core Dairy, which will include building on foodservice success in China and developing new markets, particularly in the Asia Pacific region.

They have also changed their operating model so they are better connected with customers. Fonterra has been criticised in the past for a lack of empathy and understanding of customer needs. The changes see the company divided up geographically by market rather than by product. The three new divisions will be Asia Pacific – led by Judith Swales; Africa, Middle East, Europe, North Asia, and the Americas – led by Kelvin Wickham; and Greater China – whose leader is yet to be appointed.

Changes at the board level
Fonterra is reassessing who should lead its board through its new strategy. The current chair, John Monaghan, is due to retire by rotation in 2020 but says he will be working with the board on the leadership succession plan. At this stage there has been no indication whether Monaghan will seek re-election, but it should not be assumed that he will retire next year. Given there is no assurance he would be re-elected if he choose to stand, this forward planning
by the board is imperative. Shareholders are likely to be looking much more closely at the skills, attributes and values board members can bring to the table as they look for a leadership team that can return Fonterra to a profitable operation.

Independent director Simon Israel has announced he will step down from the board at the next annual meeting in November when his current term expires. Israel has served six years on the Fonterra board. Fonterra has said Mr Israel’s decision is in support of planned succession and the need to phase the refresh of the Co-op’s independent directors.

Shareholder elected directors Donna Smit and Andy Macfarlane are standing for re-election this year, alongside newcomers Phillip Haas and Cathy Quinn. Smit joined the Board in late 2016 and Macfarlane the following year, so both joined well after the ill-fated decisions to invest in China farms and Beingmate were made.

The Fonterra board has up to 11 members, with seven elected by shareholders and four appointed by the Board and approved by shareholders.

The season ahead

Fonterra has maintained its milk price forecast of $6.25-$7.25/kg MS for the 2019-20 season. We maintain our own forecast at $7/kg MS, which is supported by the current strength in commodity prices and the recent easing of the NZD.

Earnings are forecast to be in the range of 15-25 cents per share. Under the new dividend policy where 40-60% of earnings are paid out this would equate to a dividend in the range of 6-15 cents.

Figure 5. Fonterra milk price and dividend

However, retaining a portion of the milk price remains a distinct possibility and a risk to suppliers. While cutting back payments to its farmers suppliers is certainly not something Fonterra would wish to do, it has advised ratings agencies that this is something it can do (and has previously done) to manage financial risk. Rating agencies view this flexibility as positive, as it protects the interest of creditors.
Competition between milk processors for New Zealand’s milk supply is expected to become more intense in coming years. The total supply of milk in New Zealand is expected to come under pressure as environmental and farm management regulations intensify and land moves to alternative uses.

Fonterra’s market share of New Zealand’s milk supply has steadily eroded as alternative processors expand their operations. If New Zealand’s total milk intakes fall then Fonterra’s share of this milk is likely to be eroded more quickly.

In the 2018-19 season Fonterra collected 1523m kg MS, which equates to approximately 81% of New Zealand’s total milk supply.

In the 2019-20 season Fonterra expects to collect 1,520 million kgMS, a very similar level to the previous season.

**Figure 6. Farmgate milk price, historic and forecast**

![Figure 6. Farmgate milk price, historic and forecast](image)

Source: Fonterra, ANZ Research

**Figure 7. Farmgate milk prices, historic and forecast**

![Figure 7. Farmgate milk prices, historic and forecast](image)

Source: DCANZ, Fonterra, DairyNZ
This document is intended for ANZ's institutional, professional or wholesale clients, and not for individuals or retail persons. It should not be forwarded, copied or distributed. The information in this document is general in nature, and does not constitute personal financial product advice or take into account your objectives, financial situation or needs. This document may be restricted by law in certain jurisdictions. Persons who receive this document must inform themselves about and observe all relevant restrictions.

Disclaimer for all jurisdictions: This document is prepared and distributed in your country/region by either: Australia and New Zealand Banking Group Limited (ABN11 005 357 522) (ANZ); or its relevant subsidiary or branch (each, an Affiliate), as appropriate or as set out below.

This document is distributed on the basis that it is only for the information of the specified recipient or permitted user of the relevant website (recipients). This document is solely for informational purposes and nothing contained within is intended to be an invitation, solicitation or offer by ANZ to sell, or buy, receive or provide any product or service, or to participate in a particular trading strategy. Distribution of this document to you is only as may be permissible by the laws of your jurisdiction, and is not directed to or intended for distribution or use by recipients resident or located in jurisdictions where its use or distribution would be contrary to those laws or regulations, or in jurisdictions where ANZ would be subject to additional licensing or registration requirements. Further, the products and services mentioned in this document may not be available in all countries.

ANZ in no way provides any financial, legal, taxation or investment advice to you in connection with any product or service discussed in this document. Before making any investment decision, recipients should seek independent financial, legal, tax and other relevant advice having regard to their particular circumstances.

Whilst care has been taken in the preparation of this document and the information contained within is believed to be accurate, ANZ does not represent or warrant the accuracy or completeness of the information. Further, ANZ does not accept any responsibility to inform you of any changes subsequently coming to its notice, which may affect the accuracy of the information in this document.

Preparation of this document and the opinions expressed in it may involve material elements of subjective judgement and analysis. Unless specifically stated otherwise: they are current on the date of this document and are subject to change without notice; and, all price information is indicative only. Any opinions expressed in this document are subject to change at any time without notice.

ANZ does not guarantee the performance of any product mentioned in this document. All investments entail a risk and may result in both profits and losses. Past performance is not necessarily an indicator of future performance. The products and services described in this document may not be suitable for all investors, and transacting in these products or services may be considered risky.

ANZ expressly disclaims any responsibility and shall not be liable for any loss, damage, claim, liability, proceedings, cost or expense (Liability) arising directly or indirectly and whether in tort (including negligence), contract, equity or otherwise out of or in connection with this document to the extent permissible under relevant law. Please note, the contents of this document have not been reviewed by any regulatory body or authority in any jurisdiction.

ANZ and its Affiliates may have an interest in the subject matter of this document. They may receive fees from customers for dealing in the products or services described in this document, and their staff and introducers of business may share in such fees or remuneration that may be influenced by total sales, at all times received and/or apportioned in accordance with local regulatory requirements. Further, they or their customers may have or have had interests or long or short positions in the products or services described in this document, and may at any time make purchases and/or sales in them as principal or agent, as well as act (or have acted) as a market maker in such products. This document is published in accordance with ANZ's policies on conflicts of interest and ANZ maintains appropriate information barriers to control the flow of information between businesses within it and its Affiliates.

Your ANZ point of contact can assist with any questions about this document including for further information on these disclosures of interest.

Country/region specific information: Unless stated otherwise, this document is distributed by Australia and New Zealand Banking Group Limited (ANZ).

Australia. ANZ holds an Australian Financial Services licence no. 234527. For a copy of ANZ’s Financial Services Guide please click here or request from your ANZ point of contact. If trading strategies or recommendations are included in this document, they are solely for the information of ‘wholesale clients’ (as defined in section 761G of the Corporations Act 2001 Cth).

Brazil, Brunei, India, Japan, Kuwait, Malaysia, Switzerland, Taiwan. This document is distributed in each of these jurisdictions by ANZ on a cross-border basis.

Cambodia. This document is distributed in Cambodia by ANZ Royal Bank (Cambodia) Limited (ANZ Royal Bank). The recipient acknowledges that although ANZ Royal Bank is a subsidiary of ANZ, it is a separate entity to ANZ and the obligations of ANZ Royal Bank do not constitute deposits or other liabilities of ANZ and ANZ is not required to meet the obligations of ANZ Royal Bank.

European Economic Area (EEA): United Kingdom. ANZ is authorised in the United Kingdom by the Prudential Regulation Authority (PRA) and is subject to regulation by the Financial Conduct Authority (FCA) and limited regulation by the PRA. Details about the extent of our regulation by the PRA are available from us on request. This document is distributed in the United Kingdom by Australia and New Zealand Banking Group Limited ANZ solely for the information of persons who would come within the FCA definition of “eligible counterparty” or “professional client”. It is not intended for and must not be distributed to any person who would come within the FCA definition of “retail client”. Nothing here excludes or restricts any duty or liability to a customer which ANZ may have under the UK Financial Services and Markets Act 2000 or under the regulatory system as defined in the Rules of the Prudential Regulation Authority (PRA) and the FCA. ANZ is authorised in the United Kingdom by the PRA and is subject to regulation by the FCA and limited regulation by the PRA. Details about the extent of our regulation by the PRA are available from us on request.

Fiji. For Fiji regulatory purposes, this document and any views and recommendations are not to be deemed as investment advice. Fiji investors must seek licensed professional advice should they wish to make any investment in relation to this document.

Hong Kong. This publication is issued or distributed in Hong Kong by the Hong Kong branch of ANZ, which is registered at the Hong Kong Monetary Authority to conduct Type 1 (dealing in securities), Type 4 (advising on securities) and Type 6 (advising on corporate finance) regulated activities. The contents of this publication have not been reviewed by any regulatory authority in Hong Kong.

India. If this document is received in India, only you (the specified recipient) may print it provided that before doing so, you specify on it your name and place of printing.

Important notice

This publication is issued or distributed in Fiji by the Fiji branch of ANZ. It is registered at the Reserve Bank of Fiji to conduct Type 4 (advising on securities) regulated activity. The contents of this publication have not been reviewed by any regulatory authority in Fiji.
Important notice

Myanmar. This publication is intended to be general and part of ANZ's customer service and marketing activities when implementing its functions as a licensed bank. This publication is not Securities Investment Advice (as that term is defined in the Myanmar Securities Transaction Law 2013).

New Zealand. This document is intended to be of a general nature, does not take into account your financial situation or goals, and is not a personalised adviser service under the Financial Advisers Act 2008 (FAA).

Oman. ANZ neither has a registered business presence nor a representative office in Oman and does not undertake banking business or provide financial services in Oman. Consequently ANZ is not regulated by either the Central Bank of Oman or Oman's Capital Market Authority. The information contained in this document is for discussion purposes only and neither constitutes an offer of securities in Oman as contemplated by the Commercial Companies Law of Oman (Royal Decree 4/74) nor does it constitute an offer to sell, or the solicitation of any offer to buy non-Omani securities in Oman as contemplated by Article 139 of the Executive Regulations to the Capital Market Law (issued vide CMA Decision 1/2009). ANZ does not solicit business in Oman and the only circumstances in which ANZ sends information or material describing financial products or financial services to recipients in Oman, is where such information or material has been requested from ANZ and the recipient understands, acknowledges and agrees that this document has not been approved by the CBO, the CMA or any other regulatory body or authority in Oman. ANZ does not market, offer, sell or distribute any financial or investment products or services in Oman and no subscription to any securities, products or services described in this document or material is intended for Omani investment, legal, tax, accounting or other professional advice.

People’s Republic of China (PRC). This document may be distributed by either ANZ or Australia and New Zealand Bank (China) Company Limited (ANZ China). Recipients must comply with all applicable laws and regulations of PRC, including any prohibitions on speculative transactions and CNY/CNH arbitrage trading. If this document is distributed by ANZ or an Affiliate (other than ANZ China), the following statement and the text below is applicable: No action has been taken by ANZ or any affiliate which would permit a public offering of any products or services of such an entity or distribution or re-distribution of this document in the PRC. Accordingly, the products and services of such entities are not being offered or sold within the PRC by means of this document or any other document. This document may not be distributed, re-distributed or published in the PRC, except under circumstances that will result in compliance with any applicable laws and regulations. If and when the material accompanying this document relates to the products and/or services of ANZ China, the following statement and the text below is applicable: This document is distributed by ANZ China in the Mainland of the PRC.

Qatar. This document has not been, and will not be:
- lodged or registered with, or reviewed or approved by, the Qatar Central Bank (QCB), the Qatar Financial Centre (QFC) Authority, QFC Regulatory Authority or any other authority in the State of Qatar (Qatar); or
- authorised or licensed for distribution in Qatar, and
- the information contained in this document is not, and is not intended to, constitute a public offer or other invitation in respect of securities in Qatar or the QFC. The financial products or services described in this document have not been, and will not be:
  - registered with the QCB, QFC Authority, QFC Regulatory Authority or any other governmental authority in Qatar; or
  - authorised or licensed for offering, marketing, issue or sale, directly or indirectly, in Qatar.

Accordingly, the financial products or services described in this document are not being, and will not be, offered, issued or sold in Qatar, and this document is not, and will not be, distributed in Qatar. The offering, marketing, issue and sale of the financial products or services described in this document and distribution of this document is being made in, and is subject to the laws, regulations and rules of jurisdictions outside of Qatar and the QFC. Recipients of this document must abide by this restriction and not distribute this document in breach of this restriction. This document is being sent/issued to a limited number of institutional and/or sophisticated investors (i) upon their request and confirmation that they understand the statements above; and (ii) on the condition that it will not be provided to any person other than the original recipient, and is not for general circulation and may not be reproduced or used for any other purpose.

Singapore. This document is distributed in Singapore by the Singapore branch of ANZ solely for the information of "accredited investors," "expert investors" or (as the case may be) "institutional investors" (each term as defined in the Securities and Futures Act Cap. 289 of Singapore). ANZ is licensed in Singapore under the Banking Act Cap. 19 of Singapore and is exempted from holding a financial adviser's licence under Section 23(1)(a) of the Financial Advisers Act Cap. 100 of Singapore.

United Arab Emirates (UAE). This document is distributed in the UAE or the Dubai International Financial Centre (DIFC) (as applicable) by ANZ, and is not intended to constitute: (a) an offer of securities anywhere in the UAE; (b) the carrying on or engagement in banking, financial and/or investment consultation business in the UAE under the rules and regulations made by the Central Bank of the UAE, the Emirates Securities and Commodities Authority or the UAE Ministry of Economy; (c) an offer of securities within the Dubai International Financial Centre Markets Law (DIFCML) No. 12 of 2004; and (d) a financial promotion, as defined under the DIFCML No. 1 of 200. ANZ DIFC Branch is regulated by the Dubai Financial Services Authority (DFSA). ANZ DIFC Branch is regulated by the Dubai Financial Services Authority (DFSA). The financial products or services described in this document are only available to persons who qualify as "Professional Clients" or "Market Counterparty" in accordance with the provisions of the DFSA rules. In addition, ANZ has a representative office (ANZ Representative Office) in Abu Dhabi regulated by the Central Bank of the UAE. The ANZ Representative Office is not permitted by the Central Bank of the UAE to provide any banking services to clients in the UAE.

United States. Except where this is a FX- related document, this document is distributed in the United States by ANZ Securities, Inc. (ANZ SI) which is a member of the Financial Regulatory Authority (FINRA) (www.finra.org) and registered with the SEC. ANZSI's address is 277 Park Avenue, 31st Floor, New York, NY 10172, USA (Tel: +1 212 801 9160 Fax: +1 212 801 9163). ANZSI accepts responsibility for its content. Information on any securities referred to in this document may be obtained from ANZSI upon request. This document or material is intended for institutional use only – not retail. If you are an institutional customer wishing to effect transactions in any securities referred to in this document you must contact ANZSI, not its affiliates. ANZSI is authorised as a broker-dealer only for institutional customers, not for US Persons (as “US person” is defined in Regulation S under the US Securities Act of 1933, as amended) who are individuals. If you have registered to use this website or have otherwise received this document and are a US Person who is an individual: to avoid loss, you should cease to use this website by unsubscribing or should notify the sender and you should not act on the contents of this document in any way. Non-U.S. analysts: Non-U.S. analysts may not be associated persons of ANZSI and therefore may not be subject to FINRA Rule 2242 restrictions on communications with the subject company, public appearances and trading securities held by the analysts. Where this is an FX-related document, it is distributed in the United States by ANZ’s New York Branch, which is also located at 277 Park Avenue, 31st Floor, New York, NY 10172, USA (Tel: +1 212 801 9160 Fax: +1 212 801 9163).

Vietnam. This document is distributed in Vietnam by ANZ or ANZ Bank (Vietnam) Limited, a subsidiary of ANZ.

This document has been prepared by ANZ Bank New Zealand Limited, Level 10, 171 Featherston Street, Wellington 6140, New Zealand, Ph 64-4-382 1992, e-mail nzecomics@anz.com, http://www.anz.co.nz